Abreos Biosciences and True Diagnostics have signed an agreement to collaborate on the development of point-of-care tests that can validate the identity and activity of biologics and biosimilars. This class of drugs is increasingly vital to the care of patients with cancer, autoimmune diseases and other chronic illnesses. Abreos Biosciences is pioneering point-of-care assays for biologic drugs to enable dosage authentication, counterfeit detection, and precision personalized dosing of these expensive medications.
True Diagnostics has developed a modular diagnostic platform that enables a wide array of diagnostic tests to be faster, simpler to use and more portable than any test currently available. Their combined products will allow biopharmaceutical companies, healthcare providers, and insurance payers to be assured of optimal drug quality and delivery. The low cost testing tools will not require any additional laboratory equipment and produce results in less than 10 minutes.
"Biologics are becoming the dominant therapeutic option for many serious and chronic diseases. These drugs are revolutionizing medicine, but are expensive and must be handled and administered very carefully. We are determined to make sure that patients receive precisely the right amount, with full confidence in the integrity of their therapy,” says Bradley Messmer, Ph.D., founder and CEO of Abreos Biosciences. “Through our simple point-of-care tests that measure and ensure the validity of these high-value biologic drugs, we will bring peace of mind to patients, healthcare providers, biopharma companies and insurers alike.”
Abreos’s Veritope™ peptide technology reagents mimic the ligand bound by a monoclonal antibody (mAb); they can be rapidly developed and used in pin-prick tests to measure the levels of any therapeutic mAb or other biologics in fluids, such as serum or blood, for improved outcomes at lower cost. True Diagnostics has innovated a lateral flow platform that has been proven over many years in tools such as pregnancy tests.
Jerry Lee, founder and CEO of True Diagnostics, says, “Currently there is no commercially available reference lab or point-of-care test that can match the affordability or accuracy of our tests. Our initial products will target the top three biologics in the US – bevacizumab (better known as Avastin®), trastuzumab (Herceptin®), and rituximab (Rituxan®). Our technologies will accelerate future growth channels for pharma and biotech companies, leading academic research centers and cancer centers as well as CROs and other clinical diagnostic firms – it’s a brighter future for all.”